{
  "hash": "aee2cc8d927fb0e70a7301a32e14b55c",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: \"Bladder Cancer in the United States: National Trends and State-Level Patterns from Global Burden of Disease (GBD), 1980-2021\"\nsubtitle: \"Burden of Bladder Cancer in the United States\"\nauthor: \n  - name: Alireza Sadeghi\n    corresponding: true\n    orcid: 0000-0002-7950-3270\n    email: alireza.sadeghi.md@gmail.com\n    degrees: MD\n    affiliations: \n      - ref: shiraz\n    roles: [conceptualization, data curation, formal analysis, investigation, methodology, software, visualization, writing – review & editing, writing – original draft]\n  - name: Fatemeh Nouri\n    orcid: 0000-0002-4878-7848\n    corresponding: false\n    email: nouri.fatmh@gmail.com\n    degrees: MD\n    roles: [writing – review & editing, writing – original draft, investigation]\n    affiliations: \n      - ref: shiraz\n  - name: Niloofar Dehdari Ebrahimi\n    orcid: 0000-0002-9866-8361\n    corresponding: false\n    email: niloofar.dehdari6021@gmail.com\n    degrees: MD\n    roles: [writing – original draft, writing – review & editing, data curation, investigation]\n    affiliations: \n      - ref: shiraz\n  - name: Ehsan Taherifard\n    orcid: 0000-0002-8438-4990\n    corresponding: false\n    email: etaherim123@gmail.com\n    degrees: MD\n    roles: [writing – review & editing, resources, data curation, investigation]\n    affiliations: \n      - ref: shiraz\n  - name: Wassim Kassouf\n    corresponding: true\n    orcid: 0000-0002-8350-0531\n    email: Wassim.Kassouf.med@ssss.gouv.qc.ca\n    degrees: MD\n    roles: [writing – review & editing, supervision, project administration, investigation]\n    affiliations: \n      - ref: mcgill\naffiliations: \n  - id: shiraz\n    name: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran\n  - id: mcgill\n    name: Division of Urology, McGill University Health Center, Montreal, QC\nkeywords: \n  - bladder cancer\n  - global burden of disease\n  - United States of America\n  - incidence\n  - mortality\n  - prevalence\nnumber-sections: true\nbibliography: bladder.bib\ncsl: vancouver.csl\n# format:\n#   docx:\n#     reference-doc: reference.docx\n# filters: \neditor_options: \n  chunk_output_type: console\neditor:\n  markdown:\n    canonical: false\n    wrap: 100\n---\n\n::: {.cell}\n\n```{.css .cell-code .hidden}\n.body-justified p {\n  text-align: justify\n}\n```\n:::\n\n::: {.cell .hidden}\n\n```{.r .cell-code .hidden}\n# Setting up the quarto notebook\n\noptions(\n  tidyverse.quiet = TRUE,\n  dplyr.summarise.inform = TRUE\n)\n\nlibrary(tidyverse)\nlibrary(scales)\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\n\nAttaching package: 'scales'\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nThe following object is masked from 'package:purrr':\n\n    discard\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nThe following object is masked from 'package:readr':\n\n    col_factor\n```\n\n\n:::\n\n```{.r .cell-code .hidden}\nlibrary(glue)\nlibrary(geofacet)\nlibrary(ggnewscale)\nlibrary(future)\nlibrary(furrr)\nlibrary(gganimate)\nlibrary(paletteer)\nlibrary(flextable)\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\n\nAttaching package: 'flextable'\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nThe following object is masked from 'package:purrr':\n\n    compose\n```\n\n\n:::\n\n```{.r .cell-code .hidden}\nbladder_data <- \n  paste0(\"data/\", list.files(\"data\", \"rds\")) %>%\n  map_df(read_rds, .progress = T) %>% \n  bind_rows()\n\n\nstateids <- \n  bladder_data %>% \n  filter(location_level == \"United States of America\") %>% \n  distinct(location_id) %>%\n  as_vector()\n\nsource(\"scripts/functions.r\")\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# Creating the geofacet plot\n\ngeofac_data <- \n  bladder_data %>% \n  filter(location_id %in% c(stateids, 102)) %>% \n  group_by(measure_name, cause_name, metric_name) %>% \n  nest() %>% \n  ungroup()\n\n\npmap(geofac_data, geofacet_state_plot, .progress = T)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# Creating the plot for comparing US performance compared to competing countries\n\n\n## Line plot\n\n\nus_performance_data <- \n  bladder_data %>% \n  filter(\n    location_id %in% c(4743, 64, 102, 44635),\n    sex_id == 1 & cause_id %in% c(468, 438) |\n      sex_id == 3 & cause_id %in% c(474, 471)\n  ) %>% \n  mutate(\n    sex_id = NULL,\n    sex_name = NULL,\n    stateabb = NULL,\n    location_level = NULL,\n    country_group = if_else(\n      location_id == 102, \n      \"United States of America\",\n      \"European Union/High-income/High SDI\"\n    )\n  ) %>% \n  group_by(cause_name, metric_name) %>% \n  nest %>% \n  ungroup() %>% \n  mutate(\n    data = \n      map(data, \\(x) {\n        \n        if (27 %in% x$age_id) {\n          \n          data <- \n            x %>% \n            filter(age_id == 27)\n          \n          attr(data, \"ageattr\") <- \"Age-standardized\"\n          \n        } else {\n          \n          data <- \n            x %>% \n            filter(age_id == 22)\n          \n          attr(data, \"ageattr\") <- \"All Ages\"\n          \n        }\n        \n        return(data)\n      }, .progress = T)\n  )\n\n\n\npmap(us_performance_data, us_performance_plt, .progress = T)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n## Bump plot\n\n\nstates <- \n  bladder_data %>% \n  filter(!is.na(stateabb)) %>% \n  distinct(location_id, location_name, stateabb)\n\nbumpyears <- \n  c(1990, 2000, 2010, 2021)\n\nbump_data <- \n  bladder_data %>% \n  group_by(cause_name, metric_name) %>% \n  nest %>% \n  ungroup %>% \n  mutate(\n    data = map(\n      data, \n      \\(x) {\n        \n        cdata <- \n          x %>% \n          select(-c(upper, lower)) %>% \n          filter(\n            year %in% bumpyears,\n            location_id %in% c(4743, 64, 102, 44635, stateids),\n            sex_id == 1 & cause_id %in% c(468, 438) |\n              sex_id == 3 & cause_id %in% c(474, 471),\n            age_id %in% c(22, 27)\n          )\n        \n        agedata <- \n          cdata %>% \n          group_by(location_id, .add = T) %>% \n          count(age_id) %>% \n          filter(age_id %in% c(22, 27)) %>%\n          arrange(age_id, n) %>%\n          group_by(age_id) %>% \n          summarise(sum = sum(n))\n        \n        if (27 %in% agedata$age_id) {\n          \n          cdata <- \n            cdata %>% \n            filter(age_id == 27)\n          \n          ageattr <- \"Age-standardized\"\n          \n        } else {\n          \n          cdata <- \n            cdata %>% \n            filter(age_id == 22)\n          \n          ageattr <- \"All Ages\"\n          \n        }\n        \n        cdata <- \n          cdata %>% \n          group_by(measure_name, year) %>% \n          arrange(val) %>% \n          mutate(rank = row_number()) %>% \n          arrange(measure_id, year, rank) %>% \n          mutate(order = row_number()) %>% \n          ungroup() %>% \n          mutate(\n            color = if_else(\n              location_id == 102 |\n                (\n                  year == max(.$year) & \n                    !is.na(stateabb) & \n                    !(order %>% between(6, 50))\n                ), \n              \"yes\", \"no\"),\n            stateabb = if_else(\n              is.na(stateabb),\n              location_name, stateabb\n            ), \n            stateabb = if_else(\n              stateabb == \"United States of America\",\n              \"USA\", stateabb\n            ),\n            stateabb = if_else(\n              stateabb == \"European Union\",\n              \"EU\", stateabb\n            )\n          ) %>% \n          group_by(location_name, measure_name)\n        # mutate(n = n()) %>% \n        # filter(n != 1) %>% \n        # mutate(n = NULL)\n        \n        attr(cdata, \"ageattr\") <- ageattr\n        \n        return(cdata)\n        \n      }, .progress = TRUE\n    )\n  )\n\npmap(bump_data, bumpplot, .progress = T)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# Population pyramid plots\n\n## Data preparation\n\n\npyramid_data <- \n  bladder_data %>% \n  filter(\n    age_id %in% c(1, 6:21),\n    sex_id != 3\n  ) %>% \n  select(-location_level) %>% \n  arrange(age_id) %>% \n  mutate(age_name = fct_inorder(age_name)) %>% \n  group_by(\n    # cause_name, \n    measure_name, \n    # metric_name,\n    location_name,\n  ) %>% \n  nest() %>% \n  filter(\n    !(location_name %in% \n        c(\n          \"Middle SDI\",\n          \"G20\", \n          \"Low SDI\",\n          \"Global\", \n          \"High-middle SDI\",\n          \"Low-middle SDI\"\n          )\n      )\n  )\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n## Population pyramids for 2021\n\nplan(multisession, workers = 6)\n\nfuture_pmap(\n  pyramid_data, \n  \\(data, measure_name, location_name) {\n    \n    pyramid_filename <- \n      paste0(\n        c(\n          \"fig_C\",\n          location_name, \n          \"Bladder cancer\",\n          measure_name, \n          \"Rate.svg\"\n          ), \n        collapse = \"_\"\n        )\n    \n    if (\n      file.exists(\n        paste0(\n          \"output/figures/Population pyramid - 2021/\", \n          pyramid_filename\n          )\n        )\n      ) {return()}\n    \n    pyramid_plot(\n      data = data,\n      measure_name = measure_name\n      ) %>% \n      ggsave(\n        plot = .,\n        device = \"svg\",\n        path = \"output/figures/Population pyramid - 2021/\",\n        filename = pyramid_filename,\n        width = 25,\n        height = 25,\n        units = \"cm\",\n        dpi = 600\n        )\n    },\n  .progress = TRUE\n  )\n\nplan(sequential)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n## Population pyramid - animated 1980-2021\n\n\nyears <- \n  bladder_data %>% \n  distinct(year) %>%\n  pull\n\n\nplan(multisession, workers = 6)\n\n\nfuture_pmap(pyramid_data,\n  \n  \\(\n    data,\n    measure_name,\n    location_name\n  ) {\n    \n    file_name <-\n      paste0(\n        c(\n          location_name,\n          \"Bladder cancer\",\n          measure_name,\n          \"Rate\"\n        ),\n        collapse = \"_\"\n      ) %>% \n      paste0(\n        \"output/figures/Population pyramid - animated/fig_E_\",\n        ., \n        \".gif\"\n        )\n    \n    if (file.exists(file_name)) {return(NA)}\n    \n    library(gganimate)\n    \n    plot <- \n      pyramid_plot(\n        data = data, \n        measure_name = measure_name, \n        year = years\n      )\n    \n    \n    iserror <- \n      tryCatch(\n        {\n          ggplot_build(plot)\n          FALSE\n        },\n        error = function(e) {\n          TRUE\n        }\n      )\n    \n    if (iserror) {\n      beepr::beep()\n    }\n    \n    plot <-\n      plot +\n      transition_time(year) +\n      labs(title = 'Year: {as.integer(frame_time)}') \n    \n    anim_save(\n      filename = file_name,\n      animation = plot,  \n      device = \"png\",\n      width = 25,\n      height = 25, \n      units = \"cm\", \n      res = 300\n    ) \n    \n    \n  }, \n  .progress = TRUE\n)\n\n\nplan(sequential)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# APC Plots\n\n\napc_data <- \n  bladder_data %>% \n  filter(\n    year %in% c(1990, 2000, 2010, 2021),\n    age_id %in% c(1, 6:21),\n    location_id %in% c(stateids, 102),\n    sex_id != 3,\n    metric_id == 3\n    ) %>% \n  arrange(age_id, year) %>% \n  mutate(\n    age_name = fct_inorder(age_name)\n    ) %>% \n  group_by(location_name, measure_name) %>% \n  nest\n\nplan(multisession, workers = 4)\n\nfuture_map(list(apc_plot1, apc_plot2), \\(x) pmap(apc_data, x), .progress = TRUE)\n\nplan(sequential)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# Table\n\nfile_name <-\n  paste0(\n    \"output/tables/Percent change since 1980 in \",\n    \"Bladder cancer\",\n    \" measures.docx\"\n  )\n\nchange_data <-\n    bladder_data %>%\n    filter(\n      year %in% c(2021, 1990),\n      metric_id == 3,\n      age_id == 27,\n      sex_id != 3,\n      !(location_id %in% c(1, 44639, 44634, 44586, 44636, 44637))\n    ) %>%\n    group_by(\n      measure_name, location_name, sex_name, cause_name\n    ) %>%\n    select(1:6, 9, 10, 13:16, 18) %>%\n    # replace true value by deviations\n    mutate(upper = upper - val, lower = val - lower) %>%\n    pivot_wider(\n      id_cols = c(\n        measure_id,\n        measure_name,\n        location_id,\n        location_name,\n        sex_id,\n        sex_name,\n        cause_id,\n        cause_name,\n        stateabb\n      ),\n      names_from = year,\n      values_from = c(val, upper, lower),\n      names_glue = \"{.value}_{year}\"\n    ) %>%\n    mutate(\n      # Propagation of uncertainities\n      # references in\n      # https://chatgpt.com/share/68317e19-1f4c-800e-a8db-ec53c8621521\n      diffval = ((val_2021 - val_1990) / val_1990),\n      diffupper = diffval + ((sqrt((upper_2021^2) + (lower_1990^2))) / val_1990),\n      difflower = diffval - ((sqrt((lower_2021^2) + (upper_1990^2))) / val_1990)\n    ) %>%\n    select(-c(val_1990:lower_2021)) %>%\n    ungroup() %>%\n    mutate(\n      color = case_when(\n        diffupper > 0 & difflower > 0 ~ \"positive\",\n        diffupper < 0 & difflower < 0 ~ \"negative\",\n        sign(diffupper) != sign(difflower) ~ \"neutral\",\n      )\n    ) %>%\n    group_by(cause_name, measure_name) %>%\n    mutate(\n      upperlim = max(diffupper),\n      lowerlim = min(difflower)\n    ) %>%\n    ungroup() \n\nif (!file.exists(file_name)) {\n  \n\n  table_ggplot_data <-\n    change_data %>%\n    mutate(\n      plot = pmap(\n        list(diffval, diffupper, difflower, upperlim, lowerlim, color),\n        ggmaker,\n        .progress = TRUE\n      )\n    ) %>% \n    arrange(desc(is.na(stateabb)), location_name) %>%\n    mutate(\n      location_name = if_else(is.na(stateabb), location_name, stateabb)\n    ) %>%\n    select(\n      -c(diffval:lowerlim),\n      -contains(\"_id\"),\n      -stateabb\n    ) %>%\n    rename_with(\\(x) str_remove(x, \"_name\")) %>%\n    pivot_wider(\n      names_sep = \"_\",\n      id_cols = c(location, cause),\n      names_from = c(measure, sex),\n      values_from = plot\n    ) %>%\n    group_by(cause) %>%\n    nest() %>%\n    mutate(\n      data = if_else(\n        cause %in% c(\"Prostate cancer\", \"Testicular cancer\"),\n        map(data, \\(x) {\n          x %>%\n            select(-contains(\"Female\"))\n        }),\n        data\n      )\n    )\n\n\n  table_ggplot_data %>%\n    mutate(\n      new = map2(\n        data,\n        cause,\n        \\(x, y) fpmaker(x, y),\n        .progress = TRUE\n      )\n    )\n  \n}\n```\n:::\n\n\n\n\n**Authors contact**\n\n\n\n\n\n```{.r .cell-code .hidden}\nauthors <- rmarkdown::metadata$author\n\nauthor_data <- \n  authors |> \n  map(\\(a) {\n    tibble(\n      name         = a$name,\n      corresponding = a$corresponding %||% NA,\n      email        = a$email %||% NA,\n      orcid        = a$orcid %||% NA,\n      degrees      = a$degrees %||% NA,\n      roles        = list(a$roles),\n      affiliations = list(map_chr(a$affiliations, \"ref\"))\n    )\n  }) |> \n  list_rbind() |>       \n  unnest(c(roles, affiliations))\n\n\ncontacts_data <- \n  author_data %>% \n  distinct(name, email, orcid)\n\ncat(\n  glue_data(\n  contacts_data, \n  \"{name}\\n\\n   + Email <{email}>\\n\\n  +  ORCID [{orcid}](https://orcid.org/{orcid})\\n\\n\\n\", \n  .na = \"\"\n  )\n)\n```\n\nAlireza Sadeghi\n\n + Email <alireza.sadeghi.md@gmail.com>\n\n+  ORCID [0000-0002-7950-3270](https://orcid.org/0000-0002-7950-3270)\n\n Fatemeh Nouri\n\n + Email <nouri.fatmh@gmail.com>\n\n+  ORCID [0000-0002-4878-7848](https://orcid.org/0000-0002-4878-7848)\n\n Niloofar Dehdari Ebrahimi\n\n + Email <niloofar.dehdari6021@gmail.com>\n\n+  ORCID [0000-0002-9866-8361](https://orcid.org/0000-0002-9866-8361)\n\n Ehsan Taherifard\n\n + Email <etaherim123@gmail.com>\n\n+  ORCID [0000-0002-8438-4990](https://orcid.org/0000-0002-8438-4990)\n\n Wassim Kassouf\n\n + Email <Wassim.Kassouf.med@ssss.gouv.qc.ca>\n\n+  ORCID [0000-0002-8350-0531](https://orcid.org/0000-0002-8350-0531)\n\n{{< pagebreak >}}\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nbladder_data <-\n  bladder_data %>%\n  mutate(\n    readable_name = case_when(\n      measure_name == \"Deaths\" ~ \"mortality\",\n      measure_name == \"Prevalence\" ~ \"prevalence\",\n      measure_name == \"Incidence\" ~ \"incidence\",\n      .default = measure_name\n    )\n  )\n\ndiff_abstract <-\n  bladder_data %>%\n  filter(\n    sex_name == \"Both\",\n    year %in% c(1990, 2021),\n    location_name == \"United States of America\",\n    age_name == \"Age-standardized\"\n    ) %>%\n  group_by(measure_name) %>%\n  select(measure_name, readable_name, year, val) %>%\n  pivot_wider(names_from = year, values_from = val) %>%\n  rowwise() %>%\n  mutate(\n    diff = `2021` - `1990`,\n    than = ifelse(diff > 0, \"lower\", \"higher\"),\n    diff = paste(\n      diff %>%\n        abs %>%\n        scales::number(accuracy = 0.01),\n      than\n    )\n    )\n\nglue::glue_data(\n  diff_abstract,\n  \"In 2021, United States recorded age-standardized rates of {scales::number(2021, accuracy = 0.01)} for {readable_name}, which were {diff} than the 1990 records, respectively.\"\n)\n\n\nitems <-\n  diff_abstract %>%\n  glue::glue_data(\"{scales::number(`2021`, accuracy = 0.01)} for {readable_name} ({diff})\")\n\n# Create the final sentence\nfinal_sentence <-\n  glue::glue(\n    \"In 2021, United States recorded age-standardized rates of {knitr::combine_words(items, and = 'and ', sep = ', ')} compared to 1990 records.\"\n)\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# State abbreviations and full names for captions\n\nstate_abbs <- \n  states %>%\n  arrange(location_name) %>% \n  glue_data(\"{location_name}: {stateabb}; \") %>% \n  paste0(collapse = \"\")\n\ncountry_abbs <- \n  \"European Union: EU; SDI: Socio-Demographic Index\"\n\nmeasure_abbs <- \n  \"DALYs: Disability-Adjusted Life Year; YLDs: Years Lived with Disability; YLLs: Years of Life Lost\"\n```\n:::\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\n# Supplementary file links\n\nbase_url <- \n  \"https://github.com/alireza5969/bladder-cancer-gbd\"\n\nfigures_base_url <- \n  paste0(\n  base_url,\n  \"output/figures/\",\n  list.files(\"output/figures\")\n  )\n\ntable_base_url <- \n  paste0(\n  base_url,\n  \"output/tables/\"\n  )\n```\n:::\n\n\n\n\n::::: {.body-justified}\n\n# Abstract\n\n**Background:** United States is the country with most expenditure in health care. Yet, the\nstatistics do not correlate with the amount of money being spent. Investigating national- and\nstate-level historical trends and comparing them with other countries provides insights for policy\nmakers. \n**Aim:** We aim to explore the chronological trends in the rate of bladder cancer burden,\nincluding prevalence, incidence, mortality, Disability-Adjusted Life Year (DALY), Years Lived with\nDisability (YLD), and Years of Life Lost (YLL). State-level disparities and long-term effects of\nhealth policies were explored. \n**Methodology:** Data from Global Burden of Disease (GBD) was\nretrieved. Age- and gender-classified historical trends visualized for each state as well as the\ncountry. Trends were compared with other competing health systems, including European Union,\ncountries with high Socio-Demographic Index (SDI), and high income.\n**Results:** In 2021, United States recorded age-standardized rates of 8.35 for YLDs (0.33 lower), 3.41 for mortality (0.11 higher), 59.80 for YLLs (6.75 higher), 100.63 for prevalence (6.61 lower), 14.69 for incidence (0.51 lower), and 68.15 for DALYs (6.42 higher) compared to 1990 records.\n**Conclusion:** To reduce the significant\nand disparate burden of BC in the United States, targeted public health\ninitiatives and region-specific policies are essential. \nThese must address modifiable risk factors, improve diagnostic\nequity, and expand access to early detection and care.\n\n**Keywords:** *bladder cancer; global burden of disease; United States of America; incidence; mortality; prevalence*\n\n\n\n\n{{< pagebreak >}}\n\n\n\n\n\n\n# Introduction\n\nBladder cancer (BC) is the sixth most common cancer in the United States [@RN1]. Among American men, it\nis the fourth most common cancer and the seventh leading cause of cancer-related mortality [@RN2].\nAccording to the recent Surveillance, Epidemiology, and End Results (SEER) Program estimates,\napproximately 84,870 new cases and 17,420 deaths are projected in 2025, accounting for 4.2% of all\nnew cancer diagnoses and 2.8% of cancer-related mortality [@RN1]. Similar trends are observed\noutside the United States, specifically, a rising global burden despite declining age-standardized\nrates, highlighting that BC is a significant public health concern [@RN3].\n\nIn addition, BC imposes a high economic burden as management typically involves lifelong\nsurveillance and repeated interventions, making it the costliest cancer to treat per patient over a\nlifetime [@RN4; @RN5; @RN6]. Beyond direct healthcare costs, the disease significantly affects\npatients' quality of life as well as the emotional and practical well-being of their caregivers and\nfamilies [@RN7].\n\nWhile cigarette smoking has historically been the primary risk factor for BC [@RN8], emerging\nevidence points to a widening array of carcinogenic exposures contributing to its global incidence.\nThese include, but are not limited to, arsenic-contaminated drinking water, occupational and\ncosmetic chemicals (such as those in hair dyes), dietary factors, and pervasive environmental\npollutants [@RN9]. Despite observing a decrease in the prevalence of cigarette smoking since 1998\n[@RN10] and the implementation of stricter government regulations on the use of aryl amines, there\nhas not been a corresponding reduction in the incidence of BC [@RN11]. This stagnation suggests that\nother environmental and occupational exposures may be driving disease patterns, particularly in\nregions with inadequate regulatory oversight. One example is the elevated cancer incidence rates\nobserved in certain New England states, which have been partly attributed to environmental\ncarcinogens such as arsenic contamination in drinking water from private household wells [@RN12;\n@RN13]. The complex interplay between these exposures and persistent regional and socioeconomic\ndisparities underscores a pressing public health concern; one that remains inadequately\ncharacterized and urgently demands targeted surveillance, research, and policy intervention.\n\nPrevious studies have demonstrated substantial regional disparities in BC incidence and outcomes\nwithin the United States [@RN14; @RN15; @RN16; @RN17]. For example, Maine reports an\nage-standardized incidence rate (ASIR) of 26.7 between 2017 and 2021, nearly double that of Hawaii,\nwhich stands at 13.4 [@RN18]. Geographic variations likely stem from differences in environmental\nexposures, socioeconomic status, access to care, and healthcare infrastructure. For instance, BC\nincidence is highest in northeastern states [@RN16], while mortality tends to be greater in Southern\nstates [@RN19] where there is higher proportion of older adults, African Americans, and rural\npopulations, groups that often face delays in diagnosis and limited access to quality treatment\n[@RN20].\n<!-- Additionally, while men are more frequently diagnosed, women often experience worse -->\n<!-- outcomes, including higher stage at diagnosis and lower survival rates [@RN21]. -->\n\nWhile most BC research to date has focused on national trends or single-institution cohorts, recent,\nage-standardized comparisons at the state level are scarce. Likewise, although the Global Burden of\nDisease (GBD) project produces Disability-Adjusted Life Year (DALYs), Years Lived with Disability\n(YLDs), and Years of Life Lost (YLLs) for BC, these metrics have seen limited uptake in\ndisease-specific epidemiological studies, leaving non-fatal burden and health-system impact\nunderexplored. National analyses report that men have roughly three to four times the incidence of\nBC [@RN22] yet women present with more advanced disease and poorer survival [@RN23]; however, these\nsex-specific outcome gaps have not been systematically mapped across the states.\n\nTo address these gaps, we utilize data from the GBD 2021 study, which provides consistent estimates\nof key burden metrics for all states. This mostly-descriptive analysis offers a comprehensive\ninsight of BC burden across geographic, temporal, and age group dimensions.\n\n<!-- By incorporating [age--period--cohort]{.mark} modeling and evaluating -->\n\n<!-- sex-specific and socio-demographic patterns, our study aims to generate actionable insights for -->\n\n<!-- state-level public health planning and prioritization efforts. -->\n\n# Methodology\n\n## Study Design and Data Sources\n\nThis population-based study used data from the GBD 2021 database\n<!-- , compiled by the Institute for Health Metrics and Evaluation (IHME)  --> . GBD offers\ncomprehensive, modeled estimates for all states, enabling standardized comparisons across time,\ngeography, and socioeconomic strata, making it well-suited for analyzing disparities in BC burden on\na national and global scale. The study analyses BC (ICD-10: C67) burden across all the states of the\nUS from 1980 to 2021, assessing incidence, prevalence, mortality, YLLs, YLDs, and DALYs.\nAge-standardized rates (/100,000) were reported unless data were explicitly stated otherwise. \nThe methodology of the GBD was consistent with previous publications and the details provided in the\nAppendix. This study complies with the Guidelines for Accurate and Transparent Health Estimates\nReporting (GATHER) statement.\n\n## Definitions\n\nDALYs\n\n:   A measure of the gap in healthy years of life lived by a population as compared with a normative\n    standard. More formally, DALYs are a time based measure which adds together years of life lost\n    due to premature mortality with the equivalent number of years of life lived with disability or\n    illness.\n\nYLLs\n\n:   The component of the DALYs that measures years of life lost due to premature mortality.\n\nYLDs\n\n:   The component of the DALYs that measures lost years of healthy life through living in health\n    states of less than full health.\n\nSocio-Demographic Index (SDI)\n\n:   A composite average of the rankings of the incomes per capita, average educational attainment, and fertility rates of all areas in the GBD study.\n    \nCompeting Countries\n:   This study defines the groups of countries that are comparable with the United States \n    in the sense of development and income. These country groups include \n    European Union, high-SDI countries, and high-income countries.\n\n## Statistical Analysis\n\nWe reported age-standardized rates for each burden metric using the direct method with the GBD 2021\nworld standard population. Age-standardized rates were not applicable for *age- and sex-specific\nrate curves*. Temporal trends were calculated since 2018 until 2021. All rates were expressed per\n100,000 population. \nUncertainty intervals, used by the GBD study’s Bayesian framework, were defined\nas the 2.5th and 97.5th percentiles of 500 posterior draws from the framework and account for\nmultiple sources of uncertainty [@naghavi2024].\n\nWe used R version 4.5.1 (2025-06-13 ucrt) for calculations. In addition, 28 R packages were employed\nto facilitate data curation, visualization, analysis, and reproducibility [@allaire2024b; @allaire2024c; @atkins2025b; @attali2021a; @bååth2024a;\n@campitelli2025a; @chang2025a; @gohel2025a; @hafen2025; @hester2024; @hughes2022; @hvitfeldt2021;\n@müller2025; @pedersen2025; @richardson2025; @RJ-2021-048; @sievert2025; @sjoberg2020; @vaughan2022;\n@wickham2016; @wickham2019; @wickham2023; @wickham2025; @wilke2022; @xie2014a; @xie2015; @xie2018;\n@xie2020; @xie2025]. \nThe full methodology, including data, code, and notebooks are\ndetailed in the study's [GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd).\n\n# Results\n\n## Bladder Cancer Burden: United States Compared to Competing Countris\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nincidence_death_us_2021 <-\n  bladder_data %>%\n  filter(\n    location_name == \"United States of America\", \n    age_name == \"Age-standardized\",\n    year == 2021,\n    measure_name %in% c('Incidence', \"Deaths\"),\n    sex_name != \"Both\"\n    ) %>% \n  select(measure_name, sex_name, val, upper, lower) \n\n\nincidence_death_us_2021_txt <- \n  glue_data(\n    incidence_death_us_2021,\n    \"{number(val, .1)} [{number(lower, .1)}, {number(upper)}]\"\n  )\n\nincidence_death_compete_2021 <- \n  bladder_data %>%\n  filter(\n    is.na(stateabb), \n    age_name == \"Age-standardized\",\n    year == 2021,\n    measure_name %in% c('Incidence', \"Deaths\"),\n    sex_name == \"Both\"\n    ) %>% \n  select(measure_name, location_name, val, upper, lower)\n\n\nincidence_death_compete_2021_txt <- \n  glue_data(\n    incidence_death_compete_2021,\n    \"{number(val, .1)} [{number(lower, .1)}, {number(upper)}]\"\n  )\n```\n:::\n\n\n\n\nIn 2021, the incidence rates were 24.0 [22.4, 25.2]\nand 7.1 [6.3, 7.4], resulting in \na mortality rate of 5.8 [5.2, 6.1] and 1.7 [1.4, 1.8], respectively.\nIn the same year, European Union, high-income, and high-SDI countries \nreported mortality rates of 4.6 [4.1, 4.893], \n3.5 [3.1, 3.723], \nand \n3.4 [3.0, 3.611], respectively\nin both genders.\n\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nmax_vals_us <- \n  bladder_data %>%\n    filter(\n        measure_name %in% c('Incidence', \"Prevalence\"),\n        location_name == \"United States of America\",\n        age_name == \"Age-standardized\", \n        sex_name == \"Both\"\n    ) %>% \n    group_by(measure_name) %>% \n    slice_max(val) %>% \n    select(val, upper, lower, year)\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nAdding missing grouping variables: `measure_name`\n```\n\n\n:::\n\n```{.r .cell-code .hidden}\nmax_vals_us_txt <- \n  glue_data(\n    max_vals_us,\n    \"{number(val, .1)} [{number(lower, .1)}, {number(upper)}]\"\n    )\n```\n:::\n\n\n\n\nWith the highest age-standardized \nrates of 16.5 [15.4, 17] and 113.9 [108.3, 117] in 2011 for \nincidence and prevalence, respectively, United States has\nalmost consistently had  \nhigher incidence and prevalence of BC compared to \ncompeting countries between 1980 and 2021. \nIn contrast, DALYs, YLLs, and mortality rates \nhave been lower than competing countries 2000s.\nThe clear declining trend observable in competing countries \nis absent in the trend of United States. \nWhile these rates have been historically low in United States, \ncompeting countries have managed to \napproach to the statistics of United States (@fig-performance).\n\n![Age-standardized bladder cancer burden rates between 1980 and 2021 in the United States compared to high-income and high socio-demographic index countries and European Union.](output/figures/US performance plot/fig_B_Bladder cancer_Rate.svg){#fig-performance}\n\n\n```\nAbbreviations: DALYs: Disability-Adjusted Life Year; YLDs: Years Lived with Disability; YLLs: Years of Life Lost\n```\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\ncountry_change_data <- \n  change_data %>% \n  filter(\n    is.na(stateabb),\n    ) %>% \n  mutate(\n    sex_name = if_else(sex_id == 2, \"women\", \"men\"),\n    across(diffval:difflower, \\(x) return(abs(x) * 100))\n    )\n\ngreen_change_data <- \n  country_change_data %>% \n    filter(\n        color == \"negative\",\n        measure_name %in% c(\n          \"DALYs\", \n          \"YLLs\",\n          \"Deaths\"\n          # \"Incidence\"\n          )\n    ) %>% \n    pivot_wider(\n      values_from = diffval:difflower,\n      names_from = sex_name,\n      id_cols = c(measure_name, location_name)) %>%\n  arrange(measure_name, location_name)\n\nred_change_data <- \n  country_change_data %>% \n  filter(color == \"positive\")\n\ngreen_change_txt <- \n  glue_data(\n    green_change_data,\n    \"men: {number(diffval_men, .1)}% [{number(difflower_men, .1)}%, {number(diffupper_men, .1)}%]; women: {number(diffval_women, .1)}% [{number(difflower_women, .1)}%, {number(diffupper_women, .1)}%]\", \n    .na = \"\"\n    )\n\nincidence_green_change_data <- \n  country_change_data %>% \n    filter(\n        color %in% c(\"negative\", \"neutral\"),\n        measure_name == \"Incidence\",\n        sex_name == \"men\"\n        )\n\nincidence_green_change_txt <- \n  glue_data(\n    incidence_green_change_data,\n    \"{number(diffval, .1)}% [{number(difflower, .1)}%, {number(diffupper, .1)}%]\", \n    .na = \"\"\n    )\n\nred_change_txt <- \n  glue_data(\n    red_change_data,\n    \"{number(diffval, .1)}% [{number(difflower, .1)}%, {number(diffupper, .1)}%]\"\n    )\n```\n:::\n\n\n\n\nA more abstract but quantified version of data\nin @fig-performance could be seen in\n@tbl-percentchange which shows the percentage of age-standardized\nrates changed between 1980 and 1990 for all measures and across all states.\nSimilar to @fig-performance, the table visualizes decreased rates in\nDALYs (men: 34.6% [40.3%, 29.2%]; women: 26.6% [36.2%, 17.6%], men: 30.9% [36.8%, 25.4%]; women: 24.5% [34.4%, 15.5%], \nmen: 30.2% [36.0%, 24.2%]; women: 19.4% [29.4%, 10.8%], and men: 11.8% [20.1%, 4.6%]; women: 12.4% [23.1%, 2.1%])\nand \nYLLs (men: 36.4% [41.7%, 31.4%]; women: 28.4% [37.4%, 19.9%], men: 32.6% [38.2%, 27.5%]; women: 26.2% [35.5%, 17.4%], \nmen: 31.9% [37.4%, 26.3%]; women: 21.3% [31.3%, 12.9%], and men: 13.3% [20.3%, 7.3%]; women: 13.9% [24.2%, 4.6%])\nacross high-income and high-SDI countries, European Union,\nand United States, respectively.\nOn the other hand, while high-income and high-SDI countries, and \nEuropean Union managed to significantly \ndecrease their statistics in mortality \n(men: 30.7% [37.8%, 23.8%]; women: 26.2% [38.8%, 14.0%], men: 27.3% [34.9%, 20.4%]; women: 23.3% [36.5%, 11.0%], and \nmen: 26.6% [33.9%, 19.5%]; women: 21.3% [33.8%, 10.1%],\nrespectively) and \nmale incidence\n(15.3% [22.0%, 9.4%], 11.8% [18.5%, 5.9%],\n10.0% [17.6%, 3.2%]),\nUnited States shows insignificant changes\n(0.4% [7.9%, 5.7%]).\n\n![Percentage change of age-standardized rates between 1980 and 2021 across the United States, compared to other competing countries. Bars and error lines indicate the average percentage change and its 95% confidence interval, respectively. Green, yellow, and red indicate significant decrease, insignificant change, and significant increase in statistics, respectively.](output/tables/Percent change since 1980 in Bladder cancer measures.svg){#tbl-percentchange}\n\n```\nAbbreviations: DALYs: Disability-Adjusted Life Year; YLDs: Years Lived with Disability; YLLs: Years of Life Lost; European Union: EU; SDI: Socio-Demographic Index; Alabama: AL; Alaska: AK; Arizona: AZ; Arkansas: AR; California: CA; Colorado: CO; Connecticut: CT; Delaware: DE; District of Columbia: DC; Florida: FL; Georgia: GA; Hawaii: HI; Idaho: ID; Illinois: IL; Indiana: IN; Iowa: IA; Kansas: KS; Kentucky: KY; Louisiana: LA; Maine: ME; Maryland: MD; Massachusetts: MA; Michigan: MI; Minnesota: MN; Mississippi: MS; Missouri: MO; Montana: MT; Nebraska: NE; Nevada: NV; New Hampshire: NH; New Jersey: NJ; New Mexico: NM; New York: NY; North Carolina: NC; North Dakota: ND; Ohio: OH; Oklahoma: OK; Oregon: OR; Pennsylvania: PA; Rhode Island: RI; South Carolina: SC; South Dakota: SD; Tennessee: TN; Texas: TX; Utah: UT; Vermont: VT; Virginia: VA; Washington: WA; West Virginia: WV; Wisconsin: WI; Wyoming: WY; \n```\n\n\nAs demonstrated in @fig-pyramid, in 2021, \nall burden measures were \nhigher in men in all age groups. \nHighest rates of each burden measure among the \nage groups\nare as follows:\n\n\n\n\n\n```{.r .cell-code .hidden}\npyramid_results_data <- \n  pyramid_data %>% \n  filter(location_name == \"United States of America\") %>% \n  mutate(\n    data = map(data, \\(x) {\n      x %>% \n        group_by(sex_name) %>% \n        slice_max(val) %>% \n        ungroup() %>% \n        select(sex_name, age_name, val:lower)\n    })\n  ) %>% \n  unnest(data) %>% \n  pivot_wider(\n    id_cols = c(measure_name, age_name),\n    names_from = sex_name,\n    values_from = val:lower\n    ) \n# %>% mutate(tag = paste0(\"{#fig-pyramid-\", tolower(measure_name), \"}\"))\n\n\npyramid_results_txt <- \n  pyramid_results_data %>% \n  glue_data(\n    \"* {measure_name}: {number(val_Male, .1, big.mark = ',')} [{number(lower_Male, .1, big.mark = ',')}, {number(upper_Male, .1, big.mark = ',')}] in men and {number(val_Female, .1, big.mark = ',')} [{number(lower_Female, .1, big.mark = ',')}, {number(upper_Female, .1, big.mark = ',')}] in women in {age_name} age group.\\n\\n\\n\"\n  )\n\ncat(pyramid_results_txt)\n```\n\n* YLDs: 143.8 [108.0, 184.6] in men and 40.0 [28.7, 52.0] in women in 80+ years age group.\n\n * Prevalence: 1,635.3 [1,526.9, 1,709.5] in men and 469.3 [415.0, 502.5] in women in 75-79 years age group.\n\n * Incidence: 325.0 [274.1, 349.7] in men and 87.8 [67.6, 98.3] in women in 80+ years age group.\n\n * DALYs: 1,694.0 [1,443.1, 1,829.1] in men and 480.8 [372.3, 541.0] in women in 80+ years age group.\n\n * Deaths: 149.2 [125.3, 160.9] in men and 43.8 [33.8, 49.2] in women in 80+ years age group.\n\n * YLLs: 1,551.6 [1,310.0, 1,669.7] in men and 441.6 [361.3, 483.3] in women in 80+ years age group.\n\n\n\n\n\n::: {#fig-pyramid layout-ncol=3}\n\n![Prevalence](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_Prevalence_Rate.svg){#fig-pyramid-prevalence}\n\n![Incidence](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_Incidence_Rate.svg){#fig-pyramid-incidence}\n\n![Disability-Adjusted Life Year](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_DALYs_Rate.svg){#fig-pyramid-dalys}\n\n![Years Lived with Disability](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_YLDs_Rate.svg){#fig-pyramid-ylds}\n\n![Years of Life Lost](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_YLLs_Rate.svg){#fig-pyramid-ylls}\n\n![Mortality](output/figures/Population pyramid - 2021/fig_C_United States of America_Bladder cancer_Deaths_Rate.svg){#fig-pyramid-deaths}\n\nPopulation pyramids visualizing age-gender distribution of \nbladder cancer burden rates in United States. \n:::\n\nSimilar population pyramids visualizing each state's \nburden rates across age groups in 2021\nare available\nfrom [Supporting Files](#sup-pyramid2021) and\nthe study's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Population%20pyramid%20-%202021).\nIn addition, population pyramid plots animated based on year of \nreport are available for each each state and the country \nfrom [Supporting Files](#sup-pyramidgif) and\nthe study's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Population%20pyramid%20-%20animated).\n\n@fig-apc, similar to @fig-pyramid, presents the \nburden rates for each age group. However,\nit adds the element of time to the visualization. \nSimilar plots are available for each state\nfrom [Supporting Files](#sup-apc) and\nthe study's\n[GitHub page](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/APC%20plot%201).\n\n\n::: {#fig-apc layout-ncol=2}\n\n![Prevalence](output/figures/APC plot 1/fig_F_United States of America_Prevalence_Bladder Cancer_Rate.svg){#fig-apc-prevalence}\n\n![Incidence](output/figures/APC plot 1/fig_F_United States of America_Incidence_Bladder Cancer_Rate.svg){#fig-apc-incidence}\n\n![Disability-Adjusted Life Year](output/figures/APC plot 1/fig_F_United States of America_DALYs_Bladder Cancer_Rate.svg){#fig-apc-dalys}\n\n![Years Lived with Disability](output/figures/APC plot 1/fig_F_United States of America_YLDs_Bladder Cancer_Rate.svg){#fig-apc-ylds}\n\n![Years of Life Lost](output/figures/APC plot 1/fig_F_United States of America_YLLs_Bladder Cancer_Rate.svg){#fig-apc-ylls}\n\n![Mortality](output/figures/APC plot 1/fig_F_United States of America_Deaths_Bladder Cancer_Rate.svg){#fig-apc-deaths}\n\nAge-gender distribution of \nbladder cancer burden rates across decades in United States. \n:::\n\n\n## Bladder Cancer Burden Across the United States\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nstate_change_data <- \n  change_data %>% \n  filter(\n    !is.na(stateabb),\n    color != \"neutral\"\n    ) %>% \n  mutate(\n    sex_name = if_else(sex_id == 2, \"women\", \"men\"),\n    across(diffval:difflower, \\(x) return(abs(x) * 100))\n    )\n  \ngreen_change_data <- \n  state_change_data %>% \n  filter(color == \"negative\")\n\nred_change_data <- \n  state_change_data %>% \n  filter(color == \"positive\")\n\ngreen_change_txt <- \n  glue_data(\n    green_change_data %>%\n      arrange(-diffval) %>%\n      filter(location_name == \"New York\"),\n    \"{number(diffval, .1)}% [{number(difflower, .1)}%, {number(diffupper, .1)}%]\"\n    )\n\nred_change_txt <- \n  glue_data(\n    red_change_data,\n    \"{number(diffval, .1)}% [{number(difflower, .1)}%, {number(diffupper, .1)}%]\"\n    )\n```\n:::\n\n\n\n\nAs shown in @tbl-percentchange, while some states such as New York\n(YLLs: 33.4% [48.8%, 16.7%] and 34.9% [50.7%, 18.4%] \nin men and women, respectively; DALYs: 26.2% [43.1%, 8.1%] \nand 31.8% [49.4%, 13.0%] in men and women, respectively;\nmortality: 31.5% [47.4%, 14.7%] in women), \nwith some of the highest change percentages among the states,\nhave managed to decrease BC burden statistics, most of the states \nshow no significant change. The only state that has observed \nincreased burden is New Mexico, which reports an increased\nBC prevalence by 30.2% [3.2%, 62.6%] in men. \nState-specific, gender-stratified historical trends in \nASIR are visualized in @fig-geofacet.\nSimilar graphs for age-standardized rates of\nprevalence,\nmortality, \nDALYs,\nYLLs,\nand YLDs\nare available from [Supporting Files](#sup-geofacet) and\nthe study's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Geofacet%20plot).\n\n![State-level historical trends in age-standardized prevalence rate across the states in men and women. States are positioned to nearly resemble their geographical location.](output/figures/Geofacet plot/fig_A_Incidence_Bladder cancer_Rate.svg){#fig-geofacet}\n\n```\nAbbreviations: Alabama: AL; Alaska: AK; Arizona: AZ; Arkansas: AR; California: CA; Colorado: CO; Connecticut: CT; Delaware: DE; District of Columbia: DC; Florida: FL; Georgia: GA; Hawaii: HI; Idaho: ID; Illinois: IL; Indiana: IN; Iowa: IA; Kansas: KS; Kentucky: KY; Louisiana: LA; Maine: ME; Maryland: MD; Massachusetts: MA; Michigan: MI; Minnesota: MN; Mississippi: MS; Missouri: MO; Montana: MT; Nebraska: NE; Nevada: NV; New Hampshire: NH; New Jersey: NJ; New Mexico: NM; New York: NY; North Carolina: NC; North Dakota: ND; Ohio: OH; Oklahoma: OK; Oregon: OR; Pennsylvania: PA; Rhode Island: RI; South Carolina: SC; South Dakota: SD; Tennessee: TN; Texas: TX; Utah: UT; Vermont: VT; Virginia: VA; Washington: WA; West Virginia: WV; Wisconsin: WI; Wyoming: WY; \n```\n\n\n# Discussion\n\nThis study used GBD 2021 data to analyze trends in BC incidence, mortality, YLLs, YLDs, and DALYs in\nthe United States from 1980 to 2021. Nationally, the ASIR of BC has gradually declined since the\nlate 2010s, accompanied by a less steep decrease in the ASMR. \nThese improvements likely reflect\nadvancements in early detection strategies, enhanced treatment modalities, and broader access to\nquality healthcare services across the nation. \nHowever, these favorable national trends mask\nimportant state-level disparities. While many Northeastern states have experienced sharp declines in\nboth incidence and mortality, especially among men, certain states such as West Virginia,\nKentucky, Delaware, and Nevada have shown rising or plateauing ASIRs and ASMRs. \nAmong the states with notable trends, some have persistently stood out in terms of exceptionally high or low rates.\nMaine consistently exhibited the highest ASIR across the study period, with a declining trend in\nrecent years, whereas Hawaii showed the lowest ASIR and ASMR [Supporting Files](@sup-geofacet).\nThese differences may reflect regional\nvariations in exposure to risk factors, healthcare access, and public health interventions.\n\nDespite having one of the highest per capita health expenditures globally [@RN24], the country also\nreports one of the highest ASIR of BC compared to many high-income and high-SDI regions, a\nfinding that is consistent with recent research [@RN3]. This discrepancy likely reflects the United\nStates' advanced diagnostic infrastructure and widespread access to healthcare services [@RN25],\nwhich facilitate superior case detection rather than a true increase in disease burden [@RN26;\n@RN27]. However, this also underscores a potential misalignment in healthcare priorities, where\nsubstantial resources may be disproportionately directed toward treatment and diagnostics rather\nthan prevention and risk factor reduction [@RN28]. The persistently high incidence rates call for\nstronger public health strategies, given that recent studies indicate that approximately 80% of BC\ncases diagnosed over the past two decades are likely associated with identifiable preventable\nfactors [@RN29]. In contrast, a study suggested that inherited genetic factors are estimated to\naccount for only 7% of BC incidences in western populations [@RN30]. Given the substantial\ncontribution of known environmental risk factors, BC represents a prime candidate for targeted\npublic health policy preventive efforts, particularly in smoking cessation, occupational hazard mitigation,\nand environmental exposure reduction [@RN31].\n\nThe age distribution analysis of BC incidence, DALYs, and mortality across the states from 1990 to\n2021 reveals a consistent pattern of increasing burden with advancing age, particularly\nin older age groups, consistent with previous findings [@RN3]. While age-specific trends \nhave remained relatively stable over time, 2021 data showed slightly elevated incidence and mortality in the\noldest age groups across several states, including California, Texas, and Connecticut [Supporting Files](@sup-apc). \nThis can be partly due to the substantial aging of the overall population during this period, marked by a\n38.6% increase in the number of people aged 65 and older from 2010 to 2020 [@RN31]. In addition,\nrecent trends show the oldest Americans (especially men 85+) are not experiencing the same mortality\nimprovements as younger seniors. Notably, the most significant rise occurred in the 75-79 and 80+\nage groups, suggesting the cumulative impact of lifetime exposures and the biological role of aging\n[@RN32]. These findings suggest that while early detection and treatment may be improving overall\noutcomes, the burden in the elderly remains a critical public health concern [@RN19].\n\nConsistent with the broader literature, our own analysis confirms that men experience bladder burden rates\nof roughly four-fold higher than women [@RN22]. When we examined age-period curves\nacross multiple states, the shapes of the age‐specific burden trajectories were\nsomewhat similar for men and women in the sense that both sexes showed an exponential \nrise after age 60, despite\nwomen having much lower rates and ASMR has fallen more slowly in women than men. In\naddition, studies have shown that female patients often present with more advanced disease and\npoorer outcomes [@RN33; @RN23; @RN21]. These gender disparities are not unexpected, and one\nexplanation is that they may partly stem from previous studies suggesting that women with hematuria\noften experience delays in evaluation, as the symptom is frequently misattributed to urinary tract\ninfections or gynecologic conditions [@RN33; @RN34]. To address these disparities, clinicians should\nimplement the 2025 American Urological Association (AUA) guideline \nupdates [@RN35] in routine practice and consider the use of\nvalidated biomarkers for risk stratification, while primary care organizations are encouraged to\nadopt sex‑aware diagnostic protocols and systematically monitor referral patterns for hematuria in\nwomen.\n\nIn addition, emerging research highlights key biological contributors to these disparities: men and\nwomen differ in immune surveillance, circulating hormone levels (and hormone receptor expression),\nand genetic/epigenetic alterations [@RN36]. For example, male hormone signaling may promote certain\ncancer pathways, while female biology (e.g. different immune responses) may influence tumor\naggression [@RN37; @RN38]. Importantly, these intrinsic differences persist even after adjusting for\nknown exposures, such as smoking and occupation [@RN8]. Ongoing studies of sex hormones, immune\ncheckpoints, and genomic profiles aim to explain why men are so much more likely to develop bladder\ncancer and why women exhibit worse outcomes once diagnosed.\n\nRegarding geographic and demographic disparities in BC burden, consistent with our study,\nstudies from United States\nshow the highest incidence among males and in the Northeast region (e.g. Maine, New\nHampshire, Vermont) [@RN16]. This pattern cannot be fully explained by smoking alone [@RN12]. In\nfact, researchers have linked elevated incidence in these New England states to environmental\ncarcinogens, one of which is arsenic in drinking water using private domestic wells [@RN12; @RN13].\nDeclines in Northeast BC rates over the past decade suggest improvements in water treatment [@RN39]\nand broader public health interventions. For example, in both Maine and New Jersey, household\narsenic treatment systems, particularly those professionally installed and maintained, have\nachieved a substantial seven-fold reduction in arsenic exposure and associated cancer risk [@RN40].\nHowever, nearly 20% of these systems failed to reduce arsenic to acceptable levels, underscoring the\nimportance of proper installation, routine maintenance, and ongoing monitoring to ensure sustained\neffectiveness [@RN40]. Another example is in an effort to reduce arsenic-related health risks such\nas BC, New Hampshire lowered its public drinking water arsenic standard to 5 µg/L, which is \nhalf the federal Environmental Protection Agency (EPA)\nlimit, through a law passed in 2019 and implemented in 2021 [@RN41]. Despite public health\nefforts, these states continue to lead in BC incidence partly due to the disease's long latency and\nlifetime cumulative arsenic exposure. Recent reductions in arsenic levels will take time to\ntranslate into lower rates, especially as many private wells still contain legacy contamination.\n\nBy contrast, certain other regions exhibit disproportionately high mortality from BC even if\nincidence is not highest. For example, we found that Nevada and some southern states like West\nVirginia, Kentucky, and Alabama show some of the nation's highest ASMRs from BC, similar to previous\nstudies [@RN42; @RN19]. The elevated BC mortality observed in the Southern states may be partly\nexplained by the substantial burden of smoking-attributable cancer deaths in this region [@RN43]. In\naddition, the higher proportion of rural areas in southern states may contribute to increased\nmortality risk [@RN44; @RN45], potentially due to limited access to healthcare services and delayed\ncancer detection or treatment [@RN45]. Limited availability of healthcare providers and the need for\nlong-distance travel to treatment centers can cause further delays [@RN46], while lower insurance\ncoverage rates among rural residents have been reported as contributing factors to diagnostic delays\nin other cancers [@RN47]. On the contrary, Northeast's low uninsured rate [@RN48] may contribute to\nrelatively lower BC mortality, despite the region's relatively high incidence rates. As a result, a\nregional \"mismatch\" becomes evident as states like those in New England exhibit high incidence but\nrelatively low mortality, while others in the South and West experience persistently high death\nrates despite comparable or lower incidence.\n\nHawaii stands out with one of the lowest state-level BC burden rates and trends. Several factors likely\ncontribute to Hawaii's protective profile. The population is predominantly Asian/Pacific Islander,\ngroups that historically have lower BC risk than non-Hispanic Whites [@RN49]. Hawaii also boasts low\nadult smoking prevalence [@RN50] and strong tobacco-control policies relative to many mainland\nstates [@RN51]. Environmental exposures such as industrial chemicals, arsenic, pollutants, are generally\nless concentrated in Hawaii. In combination, these demographic and lifestyle differences along\nwith relatively good access to healthcare and high rates of health insurance [@RN52] likely\nexplain why Hawaii has the least BC burden despite excellent longevity. In summary, Hawaii's example\nunderscores how reduced exposure to known risks (e.g. tobacco and toxins) and access to care can produce\nstrikingly lower BC incidence and mortality.\n\nStrengths of our study include in the use of robust population-based data to examine\nstate-level disparities and temporal trends in BC incidence and mortality across the United States.\nThis study has several limitations that warrant consideration. The GBD\nanalysis is constrained by the limited availability of high-quality primary data, necessitating the\nuse of modeling techniques that may compromise predictive validity in settings where data are sparse\nor inconsistent. While the sophisticated data processing and statistical modeling methods employed\nby GBD collaborators help mitigate this issue, they also introduce an inherent level of uncertainty\ninto the estimates. In addition, there is a lag in the availability of GBD data. As our analysis is\nbased on data spanning 1990 to 2021, it may not fully capture the most recent trends in the burden\nof BC. Lastly, this study focuses primarily on the epidemiological patterns of BC and does not\nincorporate analyses of specific clinical aspects and risk factors, thereby limiting\nthe ability to draw causal inferences.\n\n# Conclusions\n\nBC remains a significant public health challenge in the United States, marked by notable geographic,\ndemographic, and sex-based disparities. Despite national declines in some burden measures,\ncertain states continue to bear a disproportionate burden, driven by environmental exposures, aging\npopulations, and limited healthcare access. Our analysis highlights the need for region-specific\nprevention policies, improved diagnostic equity, and robust surveillance systems. Addressing\nmodifiable risk factors alongside expanding access to early detection and care, is crucial. Targeted\npublic health initiatives and policies are essential to reduce disparities and alleviate the\nlong-term burden of this costly and preventable disease.\n\n---\n\n> **Comments by Fatemeh**\n> \n> [Delaware, and Nevada have shown rising or plateauing ASIRs and ASMRs. The trends shown in CDC\nexcept for NV ASMR are declining, probably because it's not age-adjusted. Anyway, focus on NV\nASMR]\n> \n> [States like the District of Columbia exhibited higher incidence and DALY rates in middle-aged males\n(50--69), potentially indicating early-life exposure to carcinogens or disparities in early\ndiagnosis. This is not age adjusted, it can be just an increase in population]\n> \n> [Among northeastern states, New York shows to have a shaper decline in ASIR and ASMR. (this may not\nbe a good comparison, because of the rural population has more incidence and NYers don't use high\ndomestic wells probably)]\n> \n> [Health Economics Research: Conduct health economic analyses to assess the cost-effectiveness of\nshifting healthcare resources towards primary prevention and early detection, compared to the\ncurrent disproportionate investment in late-stage treatment. Such research would provide crucial\nevidence for policy decisions aimed at optimizing public health spending and improving long-term\noutcomes for BC patients nationwide.]\n\n---\n\n\n# Supporting Files {.unnumbered}\n\nSupporting Files are available as appendices to the manuscript and \nfrom the following URLs.\n\n1. Plots for historical trends (geographically faceted by states) \nare available from the project's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Geofacet%20plot).[](){#sup-geofacet}\n\n2. Population pyramid plots of each state's age- and gender-stratified\nburdens in 2021 are available from the project's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Population%20pyramid%20-%202021).[](){#sup-pyramid2021} \n\n3. Animated historical population pyramid plots of each state's\nage- and gender-stratified\nburdens are available from the project's\n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Population%20pyramid%20-%20animated).[](){#sup-pyramidgif} \n\n4. Bump plots ranking states based on their \nburden statistics in 1990, 2000, 2010, and 2021 are available \nfrom the project's \n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/Bump%20plot).[](){#sup-bump} \n\n5. Line plots visualizing each state's age- and gender-stratified burdens\nacross decades are available from the project's \n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd/tree/main/output/figures/APC%20plot%201).[](){#sup-apc}\n\n\n# Statements {.appendix}\n\n## Contributions {.appendix}\n\n\n\n\n\n```{.r .cell-code .hidden}\nauthors <- rmarkdown::metadata$author\n\ndf <- \n  purrr::map_dfr(authors, function(a) {\n    tibble::tibble(\n      name = a$name,\n      role = unlist(a$roles)\n      )\n    })\n\nrole_order <- df |>\n  dplyr::distinct(role) |>\n  dplyr::pull(role)\n\nfor (r in role_order) {\n  people <- df |>\n    dplyr::filter(role == r) |>\n    dplyr::pull(name)\n\n  role_label <- stringr::str_to_sentence(r)\n\n  cat(\n    \"**\", role_label, \":** \",\n    paste(people, collapse = \", \"),\n    \"; \",\n    sep = \"\"\n  )\n}\n```\n\n**Conceptualization:** Alireza Sadeghi; **Data curation:** Alireza Sadeghi, Niloofar Dehdari Ebrahimi, Ehsan Taherifard; **Formal analysis:** Alireza Sadeghi; **Investigation:** Alireza Sadeghi, Fatemeh Nouri, Niloofar Dehdari Ebrahimi, Ehsan Taherifard, Wassim Kassouf; **Methodology:** Alireza Sadeghi; **Software:** Alireza Sadeghi; **Visualization:** Alireza Sadeghi; **Writing – review & editing:** Alireza Sadeghi, Fatemeh Nouri, Niloofar Dehdari Ebrahimi, Ehsan Taherifard, Wassim Kassouf; **Writing – original draft:** Alireza Sadeghi, Fatemeh Nouri, Niloofar Dehdari Ebrahimi; **Resources:** Ehsan Taherifard; **Supervision:** Wassim Kassouf; **Project administration:** Wassim Kassouf; \n\n\n\n\n## Acknowledgments {.appendix}\n\nThe authors declare no conflicts of interest.\n\n## Transparency Statement {.appendix}\n\nThe lead author, Alireza Sadeghi, affirms that this manuscript is an honest, accurate, and\ntransparent account of the study being reported; that no important aspects of the study have been\nomitted; and that any discrepancies from the study as planned (and, if relevant, registered) have\nbeen explained.\n\n## Data Availability Statement {.appendix}\n\nThe data utilized in this study are publicly available through the [Global Burden of Disease (GBD) Study 2021 repository](http://ghdx.healthdata.org/gbd-results-tool). \nThe data and code used to produce this manuscript \nare available from the study's \n[GitHub repository](https://github.com/alireza5969/bladder-cancer-gbd). \nData is available in R's native binary file format (RDS).\nTo reproduce the manuscript and the results, \nclone the project repository and render *index.qmd* file.\n\n## Conflicts of Interest {.appendix}\n\nThe authors declare no conflicts of interest.\n\n# References {.unnumbered}\n\n::: {#refs}\n:::\n\n:::::",
    "supporting": [
      "index_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": null,
    "postProcess": false
  }
}